<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pathol Oncol Res</journal-id><journal-id journal-id-type="iso-abbrev">Pathol. Oncol. Res</journal-id><journal-title-group><journal-title>Pathology Oncology Research</journal-title></journal-title-group><issn pub-type="ppub">1219-4956</issn><issn pub-type="epub">1532-2807</issn><publisher><publisher-name>Springer Netherlands</publisher-name><publisher-loc>Dordrecht</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6815323</article-id><article-id pub-id-type="publisher-id">488</article-id><article-id pub-id-type="doi">10.1007/s12253-018-0488-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Role of Testin in Human Cancers</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Popiel</surname><given-names>Aneta</given-names></name><address><phone>+48 608 260 692</phone><email>aneta.popiel@live.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kobierzycki</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dzi&#x00119;giel</surname><given-names>Piotr</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.4495.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 1090 049X</institution-id><institution>Division of Histology and Embryology, Department of Human Morphology and Embryology, </institution><institution>Wroclaw Medical University, </institution></institution-wrap>Wroclaw, Poland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.4495.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 1090 049X</institution-id><institution>Wroclaw Medical University, </institution></institution-wrap>Wroclaw, Poland </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="ppub"><year>2019</year></pub-date><volume>25</volume><issue>4</issue><fpage>1279</fpage><lpage>1284</lpage><history><date date-type="received"><day>29</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Testin is a protein expressed in almost all normal human tissues. It locates in the cytoplasm along stress fibers being recruited to focal adhesions. Together with zyxin and vasodilator stimulated protein it forms complexes with various cytoskeleton proteins such as actin, talin and paxilin. They jointly play significant role in cell motility and adhesion. In addition, their involvement in the cell cycle has been demonstrated. Expression of testin protein level correlates positively with percentage of cells in G1 phase, while overexpression can induce apoptosis and decreased colony forming ability. Decreased testin expression associate with loss by cells epithelial morphology and gain migratory and invasive properties of mesenchymal cells. Latest reports indicate that <italic>TES</italic> is a tumor suppressor gene which can contribute to cancerogenesis but the mechanism of loss <italic>TES</italic> gene expression is still unknown. Some authors point out hypermethylation of the CpG island as a main factor, however loss of heterozygosity may also play an important role [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The altered expression of testin was found in malignant neoplasm, <italic>i.a.</italic> ovarian, lung, head and neck squamous cell cancer, breast, endometrial, colorectal, prostate and gastric cancers [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Testin participate in the processes of tumor growth, angiogenesis, and metastasis [<xref ref-type="bibr" rid="CR10">10</xref>]. Many researchers stated involvement of testin in tumor progression, what suggest its potential usage in immunotherapy [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Understanding the molecular functions of testin may be crucial in development personalized treatment. In the present manuscript up-to-date review of literature can be found.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Testin</kwd><kwd>Cancerogenesis</kwd><kwd>Breast cancer</kwd><kwd>Ovarian cancer</kwd><kwd>Gastrointestinal cancers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Ar&#x000e1;nyi Lajos Foundation 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><sec id="FPar1"><title>Testin in Physiology</title><p id="Par2">Testin is a protein with a molecular mass 47&#x000a0;kDa encoded by <italic>TES</italic> gene located on the fragile site FRA7G at 7q31.2 [<xref ref-type="bibr" rid="CR6">6</xref>]. It is localized in the cytoplasm, along stress fibers and is recruited to focal adhesions [<xref ref-type="bibr" rid="CR12">12</xref>]. The protein is composed of N-terminal PET (Prickle, Espinas, <italic>TES</italic>) and C-terminal three LIM (lin&#x02013;11, isl-1, mec-3) domains [<xref ref-type="bibr" rid="CR13">13</xref>]. At its COOH terminal (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>), the testin protein has three zinc-binding domain linked by two amino-acids spacer which play role in focal adhesion. LIM family proteins have been found to be a part of cytoskeleton [<xref ref-type="bibr" rid="CR14">14</xref>]. They are responsible for protein-protein interactions coordinating signaling intracellular pathways [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. The N-terminal and C-terminal halves of the protein can interact with each other, hence hindering interaction with other cytoskeleton associated protein such as: zyxin, vasodilator stimulated protein (VASP), talin, nuclear actin related protein (Arp7A) and actin [<xref ref-type="bibr" rid="CR17">17</xref>]. They are together acting as integrating partners in focal adhesion. Coutts et al. noticed that fibroblasts stably overexpressing TES have an increased ability to spread, are larger and contain increased numbers of actin protrusions [<xref ref-type="bibr" rid="CR16">16</xref>]. Testin protein overexpression had effect on cells spreading potential not on percentage of cells spread. In view of described built, testin plays significant role in the cell adhesion, cell spreading and in the reorganization at the actin cytoskeleton [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>The structure of the testin protein</p></caption><graphic xlink:href="12253_2018_488_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="FPar2"><title>Testin in Pathology</title><p id="Par3">Molecular studies characterized <italic>TES</italic> as tumor suppressor gene and reported its downregulation in many human malignancies [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In 2007 Bo&#x000eb;da et al. presented for the first time interaction between LIM3 domain of testin protein and Mena protein which is key modulator of cellular migration [<xref ref-type="bibr" rid="CR18">18</xref>]. Moreover, it was shown, that decreased expression of testin protein increased cell motility, decreased cell-cell contact and therefore have potential to be a marker of cancer metastasis [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par4">TES encodes testin protein containing a PET domain at the NH2- terminus which is involved in actin stress fibers targeting, and three LIM ((lin-1, ils-1 and mec-3) domains (LIM1, LIM2, LIM3) at the COOH-terminus. One LIM domain contain loosely conserved cysteine-rich consensus sequence including two separate zinc fingers-F1. They are separated from each other by SPACER.</p><p id="Par5">Cancers are the only investigated diseases with <italic>TES</italic> gene disruptions. It is silencing promotes cell proliferation, invasiveness ability and angiogenesis [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Important ways of <italic>TES</italic> inactivation are mechanisms of loss of heterozygosity (LOH) and hypermethylation (HMT). In LOH one or two alleles of the same gene are lost, whereas in HMT occurs abnormal DNA methylation which may inactivate suppressor genes. This phenomena were described in almost every type of cancer. Predominantly, in performed studies decreased <italic>TES</italic> gene expression associated with HMT of CpG islands nor LOH of chromosome 7q31 was found [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. In addition, methylation of <italic>TES</italic> promoter region was described in various tumor types. Tobias et al. showed methylation of the CpG islands at the 5&#x02032; end in many types of tested tumor-derived cell lines [<xref ref-type="bibr" rid="CR26">26</xref>]. Tatarelli et al. found fully methylated <italic>TES</italic> promoter in 1/10 breast, 1/8 pancreatic and 9/18 leukemia cell lines [<xref ref-type="bibr" rid="CR19">19</xref>]. According to Ma et al. methylation of CpG in the <italic>TES</italic> promoter inactivate gene. Moreover, it was revealed that treatment with 5-aza-2&#x02019;deoxycytidine (DAC), inhibitor of DNA methyltransferase activity, switched completely methylated <italic>TES</italic> promoter into partially or even fully unmethylated region in gastric cancer cell lines [<xref ref-type="bibr" rid="CR3">3</xref>]. Upregulation of <italic>TES</italic> gene expression after treatment with DAC in glioblastoma cells confirmed that HMT play significant role in <italic>TES</italic> regulation, being responsible for gene silencing [<xref ref-type="bibr" rid="CR27">27</xref>]. Only one study presented contrary results. Han et al. indicated overexpression of <italic>TES</italic> in GTL-16 gastric cancer cell line [<xref ref-type="bibr" rid="CR28">28</xref>]. High frequency of LOH was found at 7q31 region in primary gastric cancer, they identified D7S486 to be the most frequent LOH locus [<xref ref-type="bibr" rid="CR3">3</xref>]. As it was anticipated, there is an evidence presence of LOH in 7q31.2 in many types of neoplasms, e.g. ovary, breast, colorectal, gastric, head and neck, prostate, thyroid, pancreatic and kidney cancer as well in leukemias [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. Ma et al. presented correlation between LOH presence and lack of testin protein expression in gastric cancer [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Results are unequivocal as Chene et al. did not disclose such correlations in prostate cancer [<xref ref-type="bibr" rid="CR4">4</xref>].</p></sec><sec id="FPar3"><title>Testin - Epigenetic Modifications, Copy Number Alterations and Mutations Based on Available Database (GDC Data Portal, NGS Data, GEO)</title><p id="Par6">According to GDC Data Portal which analyzed 10,202 cases they identified 105 cases with different type of cancers (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Number of cases and type of cancer affected by TES mutations</p></caption><graphic xlink:href="12253_2018_488_Fig2_HTML" id="MO2"/></fig></p><p id="Par7">Analyzed patients was affected by 114 mutations of TES gene described in 21 projects. The largest number of cases was covered by endometrial carcinoma (42 cases), colorectal cancer (12) and breast cancer (7). During the process of transcription was identified missense, stop gained and frameshift mutations (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Shown the incidence of types of mutations with a predominance of missense mutations (47)</p></caption><graphic xlink:href="12253_2018_488_Fig3_HTML" id="MO3"/></fig></p><p id="Par8">The most frequent type of somatic mutation was substitution, described in 91 cases. Two authors cloned and described human TES gene. Tatarelli et al. determined that inactivation of TES is caused by methylation of CpG islands and revealed 3 missense mutation in 26 tumor cell lines [19]. In 2001 Tobias et al. showed also frequent occurrence of methylation of the CpG island at the 5-prime end in ovarian cancer and tumor-derived cell lines [<xref ref-type="bibr" rid="CR26">26</xref>]. Research on TES gene revealed that TES gene may represent tumor supressor gene.</p></sec><sec id="Sec2"><title>Role of Testin in Cancers</title><sec id="FPar4"><title>Ovarian Cancer</title><p id="Par9">According to Knudson<sup>&#x02018;</sup>s hypothesis, HMT can be the &#x0201c;second hit&#x0201d; in tumor suppressor genes inactivation [<xref ref-type="bibr" rid="CR38">38</xref>]. Previous studies showed also high frequency of <italic>TES</italic> gene HMT in the cancer cells [<xref ref-type="bibr" rid="CR26">26</xref>]. Upregulation of <italic>TES</italic> gene by DAC in ovarian cancer cell line induces cell apoptosis and reduces colony formation preventing from rapid grow of cancer cells [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Qui et al. analyzed <italic>TES</italic> expression in regard HMT and LOH using microsatellite analysis and methylation-specific PCR (MS-PCR) in epithelial ovarian cancer cell lines (SKOV3 and A2780) and ovarian cancer samples. Additionally, they demonstrated by immunohistochemistry (IHC) weak testin expression in cancer samples and strong in normal ovarian tissues [<xref ref-type="bibr" rid="CR1">1</xref>]. Mentioned study is the only one describing role of testin gene and protein in ovarian cancer. Authors did not correlate disclosed expressions with clinicopathological data.</p></sec><sec id="FPar5"><title>Breast Cancer</title><p id="Par10">Zhu et al. conducted studies analyzing association between <italic>TES</italic> gene expression and cell migratory potential tested by Transwell chamber assay as well their invasiveness (expression of matrix metalloproteinase-2; MMP-2) and angiogenesis (expression of CD34, marker of angiogenesis) by IHC. In the perspective of recognized markers they correlated with them <italic>TES</italic> expression. It seems that <italic>TES</italic> play important role not only in tumor formation but also in angiogenesis and metastasis. <italic>TES</italic> gene expression inversely correlates with expressions of MMP-2 and CD34 [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Expression of MMP-2 is regulated by miR-29b. Inhibition of MMP-2 through miR-29b can suppress tumor invasion, angiogenesis and metastasis [<xref ref-type="bibr" rid="CR41">41</xref>]. Interaction between MMP-2 and miR-29b may be useful as therapeutic target for breast cancer (BC). Sarti et al. studied IHC expression of testin in BC patients in a view of their molecular subtype (luminal A, luminal B, basal-like called triple-negative and normal-like BC). Expression of testin was decreased in 74.7% of studied samples, whereas statistically significant downregulation of testin expression was observed in triple-negative and luminal B subtypes. Furthermore, frequency of HMT of CpG in testin varied between BC subtypes and was the highest in luminal B subtype [<xref ref-type="bibr" rid="CR42">42</xref>]. Consequently, a different correlation levels between testin protein vs. triple-negative and luminal B subtypes may be the result of different grades of HMT of CpG in <italic>TES</italic> promoter region [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Low level of testin protein correlates with higher grades of histological malignancy and is unfavorable prognostic marker [<xref ref-type="bibr" rid="CR25">25</xref>]. Zhu et al. demonstrated in breast cancer (BC) correlation between low <italic>TES</italic> gene expression and shortened survival rates e.g. breast relapse-free, cause-specific, distant metastasis free and overall survival [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="FPar6"><title>Endometrial Cancer</title><p id="Par11">Dong et al. showed loss of <italic>TES</italic> gene expression in endometrial tissue using PCR. They hypothesized HMT as a main regulator of <italic>TES</italic> expression. Overexpressed <italic>TES</italic> gene significantly induce apoptosis, reduce cell proliferation and arrest cells in G1 phase of cell cycle [<xref ref-type="bibr" rid="CR2">2</xref>]. Additionally, Gu et al. measured <italic>TES</italic> gene expression by PCR in five endometrial cancer cell lines (AN3CA, Ishikawa, KLE, ECC-1, HEC-1A). They presented influence of <italic>TES</italic> gene on MMP-2. which may control cellular invasion [<xref ref-type="bibr" rid="CR20">20</xref>]. On the other hand in cancer progression important role plays epithelial-mesenchymal transition (EMT). During this process biology and structure of epithelial cells is switched into features found in mesenchymal ones, i.e. cells lose their polarity, cell-cell adhesion and gain migratory and invasive properties [<xref ref-type="bibr" rid="CR43">43</xref>]. Downregulation of <italic>TES</italic> gene was observed with decreased expression of epithelial marker- E-cadherin and increased expression of mesenchymal markers: N-cadherin, vimentin and snail. Presence of EMT markers expression significantly correlated with poor outcomes and invasiveness of cancer cell [<xref ref-type="bibr" rid="CR2">2</xref>]. Immunoexpression of testin was various in different clinical stages and histological grades. IHC analysis revealed decreased testin expression in endometrial cancer cases compared to the adjacent normal endometrium. Decreased expression of testin protein correlated with advanced tumor stage, high grade and lymphatic vascular space invasion. No correlation between testin protein expression and patient age, pathologic types, myometrial invasion and lymphatic metastasis was shown [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="FPar7"><title>Colorectal Cancer</title><p id="Par12">Li et al. described decreased expression of testin gene and protein in colorectal cancer (CRC). Additionally, they pointed correlation between low testin gene and protein expression and cell migratory as well invasive properties [<xref ref-type="bibr" rid="CR5">5</xref>]. A disabled apoptotic response may be a major contributor of tumor growth, however mechanism in which testin reduce proliferation and induce apoptosis is still unclear. Study on CRC revealed that high expression of <italic>TES</italic> gene correlate with decreased levels of the anti-apoptotic proteins such as Bcl-2, survivin and increased levels of pro-apoptotic proteins i.e. p53, Puma, Bax. In pathogenesis of sporadic CRC take part uncertain communication between cells which is altered by deviation in p38 mitogen-activated protein kinase pathway (p38-MAPK) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Studies on the role of p38 in CRC cancerogenesis are divergent. Several reports described role of p38 in cell survival and invasion in advanced tumor types whereas involvement in induced cell cycle arrest, differentiation and apoptosis was shown [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Western blot (WB) analysis performed by Li et al. on CRC cell lines overexpressing <italic>TES</italic> showed increased p38 phosphorylation. Moreover, inhibition of p38 by specific inhibitor of p38-MAPK (SB203580) markedly promoted proliferation and inhibited apoptosis of cancer cells [<xref ref-type="bibr" rid="CR5">5</xref>]. This result indicate that activation of MAPK through phosphorylation of p38 in CRC with high expression of <italic>TES</italic> gene is associated with anti-proliferative and pro-apoptotic effect [<xref ref-type="bibr" rid="CR3">3</xref>].</p></sec><sec id="FPar8"><title>Gastric Cancer</title><p id="Par13">Ma et al. analyzed expression of <italic>TES</italic> gene in gastric normal and cancer cell lines. They comprehensive analysis did not show any specific <italic>TES</italic> gene mutation. However, HMT of CpG islands observed in the region of <italic>TES</italic> gene resulted in downregulation of <italic>TES</italic> gene and protein level in primary gastric cancer [<xref ref-type="bibr" rid="CR3">3</xref>]. In another study, WB and IHC analysis showed that low protein level was associated with lower differentiation However, there was no relationship with age, sex, tumor size, metastasis, lymphatic invasion and clinical stage. Patients with positive <italic>TES</italic> expression have longer survival time [<xref ref-type="bibr" rid="CR47">47</xref>].</p></sec><sec id="FPar9"><title>Lung Cancer</title><p id="Par14">The role of testin in lung cancer is not widely described. The only work by Wang et al. describe weak <italic>TES</italic> gene and protein expression in non-small cell lung cancer (NSCLC) cell lines in regard to normal bronchial epithelial cells [<xref ref-type="bibr" rid="CR46">46</xref>]. The authors explored suppressive effect of testin on proliferation, invasion and colony forming of NSCLC cells. Flow cytometric analysis revealed induced apoptosis in NSCLC cells overexpressing <italic>TES</italic>. Additionally, they presented inhibitory effect of TES on NSCLC cell xenograft formation and growth in vivo on athymic nude mice. These data suggest important role of testin in development and progression of NSCLC [<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="FPar10"><title>Prostate Cancer</title><p id="Par15"><italic>TES</italic> gene is localized at 7q31 region which encodes also others candidate tumor suppressor genes such as <italic>CAV2, CAV1, MET, CAPZA2, ST7, WNT2</italic> [<xref ref-type="bibr" rid="CR19">19</xref>]. Quantified analysis by RT-PCR displayed that only <italic>TES</italic> gene showed decrease expression in all types of prostate tumors, supporting tumor suppressor gene hypothesis. This is in concordance with results of Tobias et al. who showed reduced growth potential in ovarian (OVCAR5) and cervical (HeLa) cancer cell lines with reduced <italic>TES</italic> gene expression. Chene et al. demonstrated decreased expression of <italic>TES</italic> in confined prostate tumors, tumors with extracapsullary extension and hormonal refractory prostate tumors. However, in hormonal refractory tumors <italic>TES</italic> gene expression was lower than in other types of prostate cancer [<xref ref-type="bibr" rid="CR24">24</xref>]. Additionally, <italic>TES</italic> gene expression was higher in prostatic epithelial cell lines than in primary prostatic fibroblast [<xref ref-type="bibr" rid="CR4">4</xref>]. However, results of study by Chene et al. did not find correlation between LOH and <italic>TES</italic> gene expression [<xref ref-type="bibr" rid="CR26">26</xref>].</p></sec><sec id="FPar11"><title>Head and Neck Squamous Cell Cancer</title><p id="Par16">Gunduz et al. analyzed <italic>TES</italic> expression in regard to clinical advancement (i.e. tumor, lymph nodes and metastasis status; TNM) and survival ratio in head and neck squamous cell cancers. They presented no association between TNM stage and <italic>TES</italic> gene expression, whereas worse survival rate (50% vs. 80%) was observed in cases with weak compared to normal and high <italic>TES</italic> expression [<xref ref-type="bibr" rid="CR8">8</xref>]. In Li et al. work expressions of testin gene and protein were measured by PCR, WB and IHC. They disclosed lower expression of testin protein in the nasopharyngeal cancer in comparison to the normal tissue. Moreover, protein expression positively correlated with lymph node and distant metastasis and differentiation grade. This protein may be useful as a prognostic tool reference to metastasis in nasopharyngeal cancer [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec></sec></sec><sec id="Sec3"><title>Conclusion</title><p id="Par17">Various studies showed that <italic>TES</italic> gene silencing can contribute to cancerogenesis revealing its nature of tumor suppressor gene. This findings may be useful in individualized therapy. Understanding molecular mechanisms of cancerogenesis are an important step forward in expanding possibilities of treatment, e.g. usage of 5-aza-2&#x02019;deoxycytidine. Moreover, there is an evidence suggesting possible usage of testin protein as a prognostic marker. Further studies are necessary to reveal, evaluate and confirm various interesting clinical implications.</p><sec id="FPar12" sec-type="data-availability"><title>Availability of Data</title><p id="Par18">The datasets analysed in the current study are available on the in the Genomic Data Commons (GDC) Data Portal at <ext-link ext-link-type="uri" xlink:href="https://gdc.cancer.gov/">https://gdc.cancer.gov/</ext-link>.</p></sec></sec></body><back><notes><title>Compliance with Ethical Standards</title><notes notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par19">The authors declare that they have no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Kong</surname><given-names>B</given-names></name></person-group><article-title>Frequent hypermethylation and loss of heterozygosity of the testis derived transcript gene in ovarian cancer</article-title><source>Cancer Sci</source><year>2010</year><volume>101</volume><fpage>1255</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2010.01497.x</pub-id><?supplied-pmid 20180808?><pub-id pub-id-type="pmid">20180808</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>R</given-names></name><name><surname>Pu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Lian</surname><given-names>K</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name></person-group><article-title>TESTIN was commonly hypermethylated and involved in the epithelial-mesenchymal transition of endometrial cancer</article-title><source>APMIS</source><year>2015</year><volume>123</volume><fpage>394</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1111/apm.12361</pub-id><?supplied-pmid 25720371?><pub-id pub-id-type="pmid">25720371</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Weng</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name></person-group><article-title>Extensive analysis of D7S486 in primary gastric cancer supports TESTIN as a candidate tumor suppressor gene</article-title><source>Mol Cancer</source><year>2010</year><volume>9</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">20051109</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ch&#x000ea;ne</surname><given-names>L</given-names></name><name><surname>Giroud</surname><given-names>C</given-names></name><name><surname>Desgrandchamps</surname><given-names>F</given-names></name><name><surname>Boccon-Gibod</surname><given-names>L</given-names></name><name><surname>Cussenot</surname><given-names>O</given-names></name><name><surname>Berthon</surname><given-names>P</given-names></name><name><surname>Latil</surname><given-names>A</given-names></name></person-group><article-title>Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene</article-title><source>Int J Cancer</source><year>2004</year><volume>111</volume><fpage>798</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1002/ijc.20337</pub-id><?supplied-pmid 15252854?><pub-id pub-id-type="pmid">15252854</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Li H, Huang K, Gao L, Wang L, Niu Y, Liu H (2016) TES inhibits colorectal cancer progression through activation of p38. Oncotagret 7</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarti</surname><given-names>M</given-names></name><name><surname>Sevignani</surname><given-names>C</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Aqeilan</surname><given-names>R</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Pentimalli</surname><given-names>F</given-names></name><name><surname>Picchio</surname><given-names>MC</given-names></name><name><surname>Godwin</surname><given-names>A</given-names></name><name><surname>Rosenberg</surname><given-names>A</given-names></name><name><surname>Drusco</surname><given-names>A</given-names></name><name><surname>Negrini</surname><given-names>M</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>Adenoviral transduction of TESTIN gene into breast and uterine Cancer cell lines promotes apoptosis and tumor reduction in vivo</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>806</fpage><lpage>813</lpage><?supplied-pmid 15701871?><pub-id pub-id-type="pmid">15701871</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>W</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>W-J</given-names></name><name><surname>Hu</surname><given-names>J-F</given-names></name><name><surname>Wang</surname><given-names>Z-Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>L-N</given-names></name></person-group><article-title>Testin is a tumor suppressor in non-small cell lung cancer</article-title><source>Oncol Rep</source><year>2017</year><volume>37</volume><fpage>1027</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.3892/or.2016.5316</pub-id><pub-id pub-id-type="pmid">28000866</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunduz</surname><given-names>Esra</given-names></name><name><surname>Gunduz</surname><given-names>Mehmet</given-names></name><name><surname>Beder</surname><given-names>Levent</given-names></name><name><surname>Nagatsuka</surname><given-names>Hitoshi</given-names></name><name><surname>Fukushima</surname><given-names>Kunihiro</given-names></name><name><surname>Sutcu</surname><given-names>Recep</given-names></name><name><surname>Delibas</surname><given-names>Namik</given-names></name><name><surname>Yamanaka</surname><given-names>Noboru</given-names></name><name><surname>Shimizu</surname><given-names>Kenji</given-names></name><name><surname>Nagai</surname><given-names>Noriyuki</given-names></name></person-group><article-title>Downregulation of TESTIN and Its Association With Cancer History and a Tendency Toward Poor Survival in Head and Neck Squamous Cell Carcinoma</article-title><source>Archives of Otolaryngology&#x02013;Head &#x00026; Neck Surgery</source><year>2009</year><volume>135</volume><issue>3</issue><fpage>254</fpage><pub-id pub-id-type="doi">10.1001/archoto.2008.560</pub-id><pub-id pub-id-type="pmid">19289703</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Li S, Xue M HL (2016) Relationship between Testin expression and clinicopathological characteristics in nasopharyngeal carcinoma patients. 310&#x02013;3</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steponaitis</surname><given-names>G</given-names></name><name><surname>Kazlauskas</surname><given-names>A</given-names></name><name><surname>Skiriute</surname><given-names>D</given-names></name><name><surname>Valiulyte</surname><given-names>I</given-names></name><name><surname>Skauminas</surname><given-names>K</given-names></name><name><surname>Tamasauskas</surname><given-names>A</given-names></name><name><surname>Vaitkiene</surname><given-names>P</given-names></name></person-group><article-title>Testin (TES) as a candidate tumour suppressor and prognostic marker in human astrocytoma</article-title><source>Oncol Lett</source><year>2016</year><volume>12</volume><fpage>3305</fpage><lpage>3311</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.5077</pub-id><?supplied-pmid 27899997?><pub-id pub-id-type="pmid">27899997</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto-Garc&#x000ed;a</surname><given-names>E</given-names></name><name><surname>D&#x000ed;az-Garc&#x000ed;a</surname><given-names>CV</given-names></name><name><surname>Garc&#x000ed;a-Ruiz</surname><given-names>I</given-names></name><name><surname>Agull&#x000f3;-Ortu&#x000f1;o</surname><given-names>MT</given-names></name></person-group><article-title>Epithelial-to-mesenchymal transition in tumor progression</article-title><source>Med Oncol</source><year>2017</year><volume>34</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1007/s12032-017-0980-8</pub-id><?supplied-pmid 28560682?><pub-id pub-id-type="pmid">28560682</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala</surname><given-names>Stefano</given-names></name><name><surname>Van Troys</surname><given-names>Marleen</given-names></name><name><surname>Medves</surname><given-names>Sandrine</given-names></name><name><surname>Catillon</surname><given-names>Marie</given-names></name><name><surname>Timmerman</surname><given-names>Evy</given-names></name><name><surname>Staes</surname><given-names>An</given-names></name><name><surname>Schaffner-Reckinger</surname><given-names>Elisabeth</given-names></name><name><surname>Gevaert</surname><given-names>Kris</given-names></name><name><surname>Ampe</surname><given-names>Christophe</given-names></name></person-group><article-title>Expanding the Interactome of TES by Exploiting TES Modules with Different Subcellular Localizations</article-title><source>Journal of Proteome Research</source><year>2017</year><volume>16</volume><issue>5</issue><fpage>2054</fpage><lpage>2071</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.7b00034</pub-id><pub-id pub-id-type="pmid">28378594</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>LIM domain protein TES changes its conformational states in different cellular compartments</article-title><source>Mol Cell Biochem</source><year>2009</year><volume>320</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s11010-008-9901-7</pub-id><?supplied-pmid 18696217?><pub-id pub-id-type="pmid">18696217</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khurana</surname><given-names>T</given-names></name><name><surname>Khurana</surname><given-names>B</given-names></name><name><surname>Noegel</surname><given-names>a a</given-names></name></person-group><article-title>LIM proteins: association with the actin cytoskeleton</article-title><source>Protoplasma</source><year>2002</year><volume>219</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s007090200000</pub-id><?supplied-pmid 11926060?><pub-id pub-id-type="pmid">11926060</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Sala S, Catillon M, Hadzic E, Schaffner-reckinger E, Troys M Van, Ampe C (2017) The PET and LIM1&#x02013;2 domains of testin contribute to intramolecular and homodimeric interactions. 1:1&#x02013;21</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeks</surname><given-names>RJ</given-names></name><name><surname>Ludgate</surname><given-names>JL</given-names></name><name><surname>LeM&#x000e9;e</surname><given-names>G</given-names></name><name><surname>Morison</surname><given-names>IM</given-names></name></person-group><article-title>TESTIN induces rapid death and suppresses proliferation in childhood B acute lymphoblastic Leukaemia cells</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0151341</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0151341</pub-id><?supplied-pmid 26985820?><pub-id pub-id-type="pmid">26985820</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldenburg</surname><given-names>J</given-names></name><name><surname>van der Krogt</surname><given-names>G</given-names></name><name><surname>Twiss</surname><given-names>F</given-names></name><name><surname>Bongaarts</surname><given-names>A</given-names></name><name><surname>Habani</surname><given-names>Y</given-names></name><name><surname>Slotman</surname><given-names>JA</given-names></name><name><surname>Houtsmuller</surname><given-names>A</given-names></name><name><surname>Huveneers</surname><given-names>S</given-names></name><name><surname>de Rooij</surname><given-names>J</given-names></name></person-group><article-title>VASP, zyxin and TES are tension-dependent members of focal Adherens junctions independent of the &#x003b1;-catenin-vinculin module</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>17225</fpage><pub-id pub-id-type="doi">10.1038/srep17225</pub-id><?supplied-pmid 26611125?><pub-id pub-id-type="pmid">26611125</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutts</surname><given-names>AS</given-names></name></person-group><article-title>TES is a novel focal adhesion protein with a role in cell spreading</article-title><source>J Cell Sci</source><year>2003</year><volume>116</volume><fpage>897</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1242/jcs.00278</pub-id><?supplied-pmid 12571287?><pub-id pub-id-type="pmid">12571287</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatarelli</surname><given-names>C</given-names></name><name><surname>Linnenbach</surname><given-names>A</given-names></name><name><surname>Mimori</surname><given-names>K</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>Characterization of the human TESTIN gene localized in the FRA7G region at 7q31</article-title><source>2 Genomics</source><year>2000</year><volume>12</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1006/geno.2000.6272</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name></person-group><article-title>TESTIN suppresses tumor growth and invasion via manipulating cell cycle progression in endometrial carcinoma</article-title><source>Med Sci Monit</source><year>2014</year><volume>20</volume><fpage>980</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.12659/MSM.890544</pub-id><?supplied-pmid 24929083?><pub-id pub-id-type="pmid">24929083</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bo&#x000eb;da</surname><given-names>B</given-names></name><name><surname>Briggs</surname><given-names>DC</given-names></name><name><surname>Higgins</surname><given-names>T</given-names></name><name><surname>Garvalov</surname><given-names>BK</given-names></name><name><surname>Fadden</surname><given-names>AJ</given-names></name><name><surname>McDonald</surname><given-names>NQ</given-names></name><name><surname>Way</surname><given-names>M</given-names></name></person-group><article-title>Tes, a specific Mena interacting partner, breaks the rules for EVH1 binding</article-title><source>Mol Cell</source><year>2007</year><volume>28</volume><fpage>1071</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.10.033</pub-id><?supplied-pmid 18158903?><pub-id pub-id-type="pmid">18158903</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffith</surname><given-names>E</given-names></name><name><surname>Coutts</surname><given-names>AS</given-names></name><name><surname>Black</surname><given-names>DM</given-names></name></person-group><article-title>Characterisation of chicken TES and its role in cell spreading and motility</article-title><source>Cell Motil Cytoskeleton</source><year>2004</year><volume>57</volume><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1002/cm.10162</pub-id><?supplied-pmid 14743347?><pub-id pub-id-type="pmid">14743347</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drusco</surname><given-names>A</given-names></name><name><surname>Zanesi</surname><given-names>N</given-names></name><name><surname>Roldo</surname><given-names>C</given-names></name><name><surname>Trapasso</surname><given-names>F</given-names></name><name><surname>Farber</surname><given-names>JL</given-names></name><name><surname>Fong</surname><given-names>LY</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>Knockout mice reveal a tumor suppressor function for Testin</article-title><source>PNAS</source><year>2005</year><volume>102</volume><fpage>10947</fpage><lpage>10951</lpage><pub-id pub-id-type="doi">10.1073/pnas.0504934102</pub-id><pub-id pub-id-type="pmid">16033868</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Moran</surname><given-names>MS</given-names></name><name><surname>Su</surname><given-names>P</given-names></name><name><surname>Haffty</surname><given-names>BG</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name></person-group><article-title>Testin is a tumor suppressor and prognostic marker in breast cancer</article-title><source>Cancer Sci</source><year>2012</year><volume>103</volume><fpage>2092</fpage><lpage>2101</lpage><pub-id pub-id-type="doi">10.1111/cas.12020</pub-id><?supplied-pmid 22957844?><pub-id pub-id-type="pmid">22957844</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarti</surname><given-names>M</given-names></name><name><surname>Pinton</surname><given-names>S</given-names></name><name><surname>Limoni</surname><given-names>C</given-names></name><name><surname>Carbone</surname><given-names>GM</given-names></name><name><surname>Pagani</surname><given-names>O</given-names></name><name><surname>Cavalli</surname><given-names>F</given-names></name><name><surname>Catapano</surname><given-names>CV</given-names></name></person-group><article-title>Differential expression of testin and survivin in breast cancer subtypes</article-title><source>Oncol Rep</source><year>2013</year><volume>30</volume><fpage>824</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.3892/or.2013.2502</pub-id><?supplied-pmid 23715752?><pub-id pub-id-type="pmid">23715752</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobias</surname><given-names>ES</given-names></name><name><surname>Hurlstone</surname><given-names>AFL</given-names></name><name><surname>Mackenzie</surname><given-names>E</given-names></name><name><surname>Mcfarlane</surname><given-names>R</given-names></name><name><surname>Black</surname><given-names>DM</given-names></name></person-group><article-title>The TES gene at 7q31 . 1 is methylated in tumours and encodes a novel growth-suppressing LIM domain protein</article-title><source>Oncogene</source><year>2001</year><volume>20</volume><fpage>2844</fpage><lpage>2853</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1204433</pub-id><pub-id pub-id-type="pmid">11420696</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>W</given-names></name><name><surname>Nutt</surname><given-names>CL</given-names></name><name><surname>Ehrich</surname><given-names>M</given-names></name><name><surname>Riemenschneider</surname><given-names>MJ</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name><name><surname>van den Boom</surname><given-names>D</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name></person-group><article-title>Downregulation of RUNX3 and TES by hypermethylation in glioblastoma</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>583</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209805</pub-id><?supplied-pmid 16909125?><pub-id pub-id-type="pmid">16909125</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>SY</given-names></name><name><surname>Druck</surname><given-names>T</given-names></name><name><surname>Huebner</surname><given-names>K</given-names></name></person-group><article-title>Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer</article-title><source>Genomics</source><year>2003</year><volume>81</volume><fpage>105</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/S0888-7543(02)00029-0</pub-id><?supplied-pmid 12620387?><pub-id pub-id-type="pmid">12620387</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>MK</given-names></name><name><surname>Pothuri</surname><given-names>B</given-names></name></person-group><article-title>Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature</article-title><source>Gynecol Oncol Res Pract</source><year>2017</year><volume>4</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s40661-017-0039-8</pub-id><?supplied-pmid 28250960?><pub-id pub-id-type="pmid">28250960</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi&#x000e8;che</surname><given-names>I</given-names></name><name><surname>Khodja a</surname><given-names>DK</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name></person-group><article-title>Genetic alteration mapping on chromosome 7 in primary breast cancer</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>1009</fpage><lpage>1016</lpage><?supplied-pmid 9815778?><pub-id pub-id-type="pmid">9815778</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zenklusen</surname><given-names>JC</given-names></name><name><surname>Thompson</surname><given-names>JC</given-names></name><name><surname>Conti</surname><given-names>CJ</given-names></name><name><surname>Klein-Szanto</surname><given-names>AJP</given-names></name></person-group><article-title>Frequent loss of heterozygosity in human primary squamous cell and Colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>1347</fpage><lpage>1350</lpage><?supplied-pmid 7882334?><pub-id pub-id-type="pmid">7882334</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Jia X, Shanmugam C, Paluri RK, Jhala NC, Behring P, Katkoori VR, Sugandha SP, Bae S (2017) Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. 8:20198&#x02013;20212. 10.18632/oncotarget.15560</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuura</surname><given-names>K</given-names></name><name><surname>Shiga</surname><given-names>K</given-names></name><name><surname>Yokoyama</surname><given-names>J</given-names></name><name><surname>Saijo</surname><given-names>S</given-names></name><name><surname>Miyagi</surname><given-names>T</given-names></name><name><surname>Takasaka</surname><given-names>T</given-names></name></person-group><article-title>Loss of heterozygosity of chromosome 9p21 and 7q31 is correlated with high incidence of recurrent tumor in head and neck squamous cell carcinoma</article-title><source>Anticancer Res</source><year>1998</year><volume>18</volume><fpage>453</fpage><lpage>458</lpage><?supplied-pmid 9568119?><pub-id pub-id-type="pmid">9568119</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname><given-names>M</given-names></name><name><surname>Tasaka</surname><given-names>T</given-names></name><name><surname>Spira</surname><given-names>S</given-names></name><name><surname>Tsuruoka</surname><given-names>N</given-names></name><name><surname>Phillip Koeffler</surname><given-names>H</given-names></name></person-group><article-title>Allelotyping of acute myelogenous leukemia: loss of heterozygosity at 7q31.1 (D7S486) and q33-34 (D7S498, D7S505)</article-title><source>Leuk Res</source><year>1999</year><volume>23</volume><fpage>307</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/S0145-2126(98)00159-3</pub-id><?supplied-pmid 10071086?><pub-id pub-id-type="pmid">10071086</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeks</surname><given-names>RJ</given-names></name><name><surname>Kees</surname><given-names>UR</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Morison</surname><given-names>IM</given-names></name></person-group><article-title>Silencing of TESTIN by dense biallelic promoter methylation is the most common molecular event in childhood acute lymphoblastic leukaemia</article-title><source>Mol Cancer</source><year>2010</year><volume>9</volume><fpage>163</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-9-163</pub-id><?supplied-pmid 20573277?><pub-id pub-id-type="pmid">20573277</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shridhar</surname><given-names>V</given-names></name><name><surname>Sun</surname><given-names>QC</given-names></name><name><surname>Miller</surname><given-names>OJ</given-names></name><name><surname>Kalemkerian</surname><given-names>GP</given-names></name><name><surname>Petros</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>DI</given-names></name></person-group><article-title>Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas</article-title><source>Oncogene</source><year>1997</year><volume>15</volume><fpage>2727</fpage><lpage>2733</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1201448</pub-id><?supplied-pmid 9400999?><pub-id pub-id-type="pmid">9400999</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achille</surname><given-names>A</given-names></name><name><surname>Biasi</surname><given-names>MO</given-names></name><name><surname>Zamboni</surname><given-names>G</given-names></name><name><surname>Bogina</surname><given-names>G</given-names></name><name><surname>Magalini</surname><given-names>AR</given-names></name><name><surname>Pederzoli</surname><given-names>P</given-names></name><name><surname>Perucho</surname><given-names>M</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name></person-group><article-title>Chromosome 7q allelic losses in pancreatic carcinoma</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>3808</fpage><lpage>3813</lpage><?supplied-pmid 8706028?><pub-id pub-id-type="pmid">8706028</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hino</surname><given-names>O</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name></person-group><article-title>Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex</article-title><source>Cancer Sci</source><year>2017</year><volume>108</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/cas.13116</pub-id><?supplied-pmid 27862655?><pub-id pub-id-type="pmid">27862655</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasir</surname><given-names>A</given-names></name><name><surname>Holzer</surname><given-names>TR</given-names></name><name><surname>Man</surname><given-names>M</given-names></name><name><surname>Benjamin</surname><given-names>LE</given-names></name><name><surname>Melemed</surname><given-names>AS</given-names></name><name><surname>Schade</surname><given-names>AE</given-names></name></person-group><article-title>Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to newer anti-angiogenic therapies</article-title><source>Cancer Res</source><year>2015</year><volume>75</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s12935-017-0427-5</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>RP</given-names></name><name><surname>Patterson</surname><given-names>NL</given-names></name><name><surname>Fields</surname><given-names>GB</given-names></name><name><surname>Lindsey</surname><given-names>ML</given-names></name></person-group><source>The history of matrix metalloproteinases&#x000a0;: milestones , myths , and misperceptions. Trabslational Physiol</source><year>2012</year></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Zhuang</surname><given-names>S</given-names></name></person-group><article-title>MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression</article-title><source>Hepatology</source><year>2011</year><volume>54</volume><fpage>1729</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1002/hep.24577</pub-id><?supplied-pmid 21793034?><pub-id pub-id-type="pmid">21793034</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holm</surname><given-names>K</given-names></name><name><surname>Hegardt</surname><given-names>C</given-names></name><name><surname>Staaf</surname><given-names>J</given-names></name><name><surname>Vallon-Christersson</surname><given-names>J</given-names></name><name><surname>J&#x000f6;nsson</surname><given-names>G</given-names></name><name><surname>Olsson</surname><given-names>H</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Ringn&#x000e9;r</surname><given-names>M</given-names></name></person-group><article-title>Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns</article-title><source>Breast Cancer Res</source><year>2010</year><volume>12</volume><fpage>R36</fpage><pub-id pub-id-type="doi">10.1186/bcr2590</pub-id><?supplied-pmid 20565864?><pub-id pub-id-type="pmid">20565864</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalluri</surname><given-names>R</given-names></name><name><surname>R a</surname><given-names>W</given-names></name></person-group><article-title>Review series the basics of epithelial-mesenchymal transition</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><fpage>1420</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1172/JCI39104.1420</pub-id><?supplied-pmid 2689101?><pub-id pub-id-type="pmid">19487818</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossi</surname><given-names>V</given-names></name><name><surname>Peserico</surname><given-names>A</given-names></name><name><surname>Tezil</surname><given-names>T</given-names></name><name><surname>Simone</surname><given-names>C</given-names></name></person-group><article-title>p38&#x003b1; MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>9744</fpage><lpage>9758</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i29.9744</pub-id><?supplied-pmid 25110412?><pub-id pub-id-type="pmid">25110412</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name></person-group><article-title>Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells</article-title><source>Prostate</source><year>2013</year><volume>73</volume><fpage>835</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1002/pros.22627</pub-id><?supplied-pmid 23255296?><pub-id pub-id-type="pmid">23255296</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>L</given-names></name><name><surname>Bakiri</surname><given-names>L</given-names></name><name><surname>Stepniak</surname><given-names>E</given-names></name><name><surname>Wagner</surname><given-names>EF</given-names></name></person-group><article-title>p38alpha: a suppressor of cell proliferation and tumorigenesis</article-title><source>Cell Cycle</source><year>2007</year><volume>6</volume><fpage>2429</fpage><lpage>2433</lpage><pub-id pub-id-type="doi">10.4161/cc.6.20.4774</pub-id><?supplied-pmid 17957136?><pub-id pub-id-type="pmid">17957136</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Weng</surname><given-names>DS</given-names></name><name><surname>Pan</surname><given-names>ZZ</given-names></name><name><surname>Pan</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>PR</given-names></name><name><surname>Zhou</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>HK</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Xia</surname><given-names>JC</given-names></name></person-group><article-title>Expression and clinical significance of TESTIN in primary gastric cancer</article-title><source>Chinese J Cancer</source><year>2008</year><volume>27</volume><fpage>267</fpage><lpage>270</lpage></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Ming</given-names></name><name><surname>Wang</surname><given-names>Qian</given-names></name><name><surname>Peng</surname><given-names>Wen-Jia</given-names></name><name><surname>Hu</surname><given-names>Jun-Feng</given-names></name><name><surname>Wang</surname><given-names>Zu-Yi</given-names></name><name><surname>Liu</surname><given-names>Hao</given-names></name><name><surname>Huang</surname><given-names>Li-Nian</given-names></name></person-group><article-title>Testin is a tumor suppressor in non-small cell lung cancer</article-title><source>Oncology Reports</source><year>2016</year><volume>37</volume><issue>2</issue><fpage>1027</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.3892/or.2016.5316</pub-id><pub-id pub-id-type="pmid">28000866</pub-id></element-citation></ref></ref-list></back></article>